Abstract
Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To determine the prognostic value of the Decipher gene assay in men with biopsy-confirmed clinically localized prostate cancer before and after receiving treatment. This objective can be framed in two questions following the population, index prognostic factor, comparator prognostic factor(s), outcome, timing, and setting (PICOTS) format as illustrated in Table 1. Table 1. Review question in PICOTS format. (Table presented.).
| Original language | English (US) |
|---|---|
| Article number | CD014746 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2023 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 13 2023 |
Bibliographical note
Funding Information:Cochrane Urology supported the authors in the development of this Cochrane Review protocol. The following people conducted the editorial process for this article: Sign-off Editor (final editorial decision): Vikram M Narayan, MD, Department of Urology, Emory University, Atlanta, Georgia; Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Jennifer Mariano, Cochrane Urology; Copy Editor (copy editing and production): Andrea Takeda, Cochrane Central Production Service; Peer-reviewers (provided comments and recommended an editorial decision): Prof Chris H Bangma MD PhD, Erasmus MC Cancer Institute, department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands (clinical/content review), Daniel Shapiro, MD, University of Wisconsin School of Medicine and Public Health, William S. Middleton Memorial Veterans Hospital (clinical/content review). Sign-off Editor (final editorial decision): Vikram M Narayan, MD, Department of Urology, Emory University, Atlanta, Georgia; Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Jennifer Mariano, Cochrane Urology; Copy Editor (copy editing and production): Andrea Takeda, Cochrane Central Production Service; Peer-reviewers (provided comments and recommended an editorial decision): Prof Chris H Bangma MD PhD, Erasmus MC Cancer Institute, department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands (clinical/content review), Daniel Shapiro, MD, University of Wisconsin School of Medicine and Public Health, William S. Middleton Memorial Veterans Hospital (clinical/content review).
Publisher Copyright:
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
